US Stock MarketDetailed Quotes
MLTX MoonLake Immunotherapeutics
- 42.490
- +0.240+0.57%
Close Apr 26 16:00 ET
- 42.490
- 0.0000.00%
Post 16:20 ET
2.67BMarket Cap-58205P/E (TTM)
43.050High42.160Low223.59KVolume42.370Open42.250Pre Close9.50MTurnover0.95%Turnover RatioLossP/E (Static)62.87MShares64.98052wk High5.39P/B997.11MFloat Cap20.35052wk Low--Dividend TTM23.47MShs Float64.980Historical High--Div YieldTTM2.11%Amplitude4.250Historical Low42.504Avg Price1Lot Size
MoonLake Immunotherapeutics Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 23.47%-42.78M | -6.45%-12.34M | 1.08%-9.25M | 41.43%-12.16M | 36.38%-9.02M | -55.89M | -11.6M | -363.27%-9.35M | -20.76M | -14.19M |
| Net income from continuing operations | 31.67%-44.08M | 52.10%-7.89M | 21.18%-11.62M | 29.07%-12.35M | 23.05%-12.22M | ---64.51M | ---16.47M | -134.44%-14.74M | ---17.42M | ---15.88M |
| Operating gains losses | -128.04%-85.25K | -145.21%-34.51K | -131.40%-23.96K | -118.18%-13.51K | -117.22%-13.27K | --304.03K | --76.34K | -47.50%76.31K | --74.29K | --77.09K |
| Depreciation and amortization | 6.47%13.16K | 0.00%3.29K | -0.09%3.29K | 0.03%3.29K | 32.23%3.29K | --12.36K | --3.29K | 45.00%3.29K | --3.29K | --2.49K |
| Other non cash items | 119.47%484.76K | 123.62%506.23K | -77.89%-46.99K | -307.53%-33.28K | 1,106.03%58.81K | --220.88K | --226.38K | ---26.42K | --16.04K | --4.88K |
| Change In working capital | -293.55%-6.22M | -431.95%-6.54M | -63.27%1.01M | 78.73%-1.26M | 249.96%568.55K | ---1.58M | --1.97M | 21.99%2.75M | ---5.92M | ---379.14K |
| -Change in receivables | -1,128.49%-839.73K | -187.66%-336.11K | -132.22%-100.99K | -1,083.98%-241.32K | 62.73%-161.32K | ---68.36K | --383.41K | 22.39%-43.49K | --24.53K | ---432.8K |
| -Change in prepaid assets | -132.43%-6.35M | -2,507.34%-7.22M | 2.62%650.1K | 68.59%-884.52K | 230.15%1.1M | ---2.73M | --299.73K | 37,766.59%633.51K | ---2.82M | ---847.95K |
| -Change in payables and accrued expense | -8.41%1.26M | -9.51%1.3M | -78.64%461.67K | 95.73%-133.76K | -141.45%-373.74K | --1.37M | --1.44M | -6.42%2.16M | ---3.13M | --901.61K |
| -Change in other current liabilities | -45.82%-222.26K | ---- | ---- | ---- | ---- | ---152.43K | ---- | ---- | ---- | ---- |
| -Change in other working capital | ---65.51K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 23.47%-42.78M | -6.45%-12.34M | 1.08%-9.25M | 41.43%-12.16M | 36.38%-9.02M | ---55.89M | ---11.6M | -363.27%-9.35M | ---20.76M | ---14.19M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 22.13%-25.18M | 1,080.30%116.87M | -312.96%-174.38M | 633,802,550.00%12.68M | 122,826.62%19.65M | -32.34M | 9.9M | -362,386.24%-42.23M | 2 | -16.01K |
| Net PPE purchase and sale | -1,677.96%-284.63K | -28,463,300.00%-284.63K | --0 | --0 | --0 | ---16.01K | ---1 | --0 | --2 | ---16.01K |
| Net investment purchase and sale | 22.97%-24.9M | 1,083.17%117.15M | -312.96%-174.38M | --12.68M | --19.65M | ---32.32M | --9.9M | ---42.23M | --0 | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 22.13%-25.18M | 1,080.30%116.87M | -312.96%-174.38M | 633,802,550.00%12.68M | 122,826.62%19.65M | ---32.34M | --9.9M | -362,386.24%-42.23M | --2 | ---16.01K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 300.78%479.7M | 749,475.71%28.42M | 0 | 331.09%451.29M | 0 | 119.69M | 3.79K | 0 | 104.69M | 15M |
| Net issuance payments of debt | --0 | --0 | --0 | --0 | --0 | ---15M | --0 | --0 | ---30M | --15M |
| Net common stock issuance | --482.45M | --31.17M | --0 | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | --0 | ---- | ---- | ---- | --0 | --3.79K | ---- | ---- | ---- | --3.79K |
| Net other financing activities | -102.04%-2.75M | ---- | ---- | ---- | ---- | --134.69M | --0 | --0 | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 300.78%479.7M | 749,475.71%28.42M | --0 | 331.09%451.29M | --0 | --119.69M | --3.79K | --0 | --104.69M | --15M |
| Net cash flow | ||||||||||
| Beginning cash position | 391.43%39.51M | 672.16%318.17M | 441.26%501.79M | 467.45%50.13M | 391.43%39.51M | --8.04M | --41.2M | 4,443.42%92.71M | --8.83M | --8.04M |
| Current changes in cash | 1,208.84%411.74M | 7,962.69%132.94M | -256.02%-183.63M | 438.34%451.8M | 1,225.00%10.62M | --31.46M | ---1.69M | -3,266.85%-51.58M | --83.92M | --801.82K |
| Effect of exchange rate changes | -981.81%-75.31K | 881.32%64.74K | -93.26%5.01K | -183.38%-144.52K | 91.77%-535 | --8.54K | ---8.29K | 7,495.82%74.33K | ---51K | ---6.5K |
| End cash Position | 1,042.04%451.17M | 1,042.04%451.17M | 672.16%318.17M | 441.26%501.79M | 467.45%50.13M | --39.51M | --39.51M | 8,018.17%41.2M | --92.71M | --8.83M |
| Free cash flow | 22.98%-43.06M | -8.91%-12.63M | 1.08%-9.25M | 41.43%-12.16M | 36.46%-9.02M | ---55.91M | ---11.6M | -360.61%-9.35M | ---20.76M | ---14.2M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg